The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, and progress of all cancer related clinical trials at the AECC. The functions of the PRMS are: a) to review and evaluate all protocols for scientific merit, feasibility, and quality;(b) to monitor accrual in order to assure that protocols meet their accrual goals in a timely fashion;(c) to ensure that there are no competing studies with completely overlapping eligibility, and that there is adequate justification and patient resources in circumstances where it may be desirable to have more than one protocol for a specific indication;and (d) to provide recommendations as to whether AECC investigator-initiated studies are of sufficient scientific merit to warrant allocation of Protocol Specific Research Support (PSRS) and/or other resources required for conduct of the study. The PRMS functions are carried out by the Protocol Review and Monitoring Committee (PRMC), a multidisciplinary group including pathologists, radiologists, biostatisticians, nurses, pharmacists, physician scientists from surgical, medical, pediatric, gynecological, and radiation oncology. PRMC members have experience in various therapeutic modalities (i.e., cytotoxic and targeted therapies, immunotherapy, radiation) and expertise in various stages of drug development (Phases I, II, 111 trials) and translational science. The PRMC performs a complete scientific, feasibility, and administrative review of all institutional investigator-initiated and industry-sponsored cancer related protocols. All NCI-sponsored protocols that have undergone prior peer review undergo an expedited administrative review for feasibility and overlapping eligibility with other trials.
The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, prioritization, and progress of all the cancer related clinical trials at the Albert Einstein Cancer Center (AECC). As an NCI designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.
|Oudin, Madeleine J; Hughes, Shannon K; Rohani, Nazanin et al. (2016) Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression. Clin Exp Metastasis 33:249-61|
|Lee, Chang-Hyun; Rimesso, Gerard; Reynolds, David M et al. (2016) Whole-Genome Sequencing and iPLEX MassARRAY Genotyping Map an EMS-Induced Mutation Affecting Cell Competition in Drosophila melanogaster. G3 (Bethesda) 6:3207-3217|
|Lee, Kyeryoung; Tosti, Elena; Edelmann, Winfried (2016) Mouse models of DNA mismatch repair in cancer research. DNA Repair (Amst) 38:140-6|
|DÃaz-Balzac, Carlos A; Rahman, Maisha; LÃ¡zaro-PeÃ±a, MarÃa I et al. (2016) Muscle- and Skin-Derived Cues Jointly Orchestrate Patterning of Somatosensory Dendrites. Curr Biol 26:2379-87|
|Dam, Tarun K; Talaga, Melanie L; Fan, Ni et al. (2016) Measuring Multivalent Binding Interactions by Isothermal Titration Calorimetry. Methods Enzymol 567:71-95|
|Ito, Kyoko; Turcotte, RaphaÃ«l; Cui, Jinhua et al. (2016) Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. Science 354:1156-1160|
|Poulin, Myles B; Schneck, Jessica L; Matico, Rosalie E et al. (2016) Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc Natl Acad Sci U S A 113:1197-201|
|Yang, Chia-Ping Huang; Yap, Eng-Hui; Xiao, Hui et al. (2016) 2-(m-Azidobenzoyl)taxol binds differentially to distinct Î²-tubulin isotypes. Proc Natl Acad Sci U S A 113:11294-11299|
|Agalliu, Ilir; Gapstur, Susan; Chen, Zigui et al. (2016) Associations of Oral Î±-, Î²-, and Î³-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol :|
|Epeldegui, Marta; Lee, Jeannette Y; MartÃnez, Anna C et al. (2016) Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res 22:328-36|
Showing the most recent 10 out of 1310 publications